Clinicopathologic Correlates of Primary Aldosteronism
Kai Duan, MD; Ozgur Mete, MD
. Primary aldosteronism is the most common cause of secondary hypertension, incurring significant cardiovascu- lar morbidity and mortality. Our understanding of this disease has evolved substantially during the past decade. Recently, the molecular basis of primary aldosteronism has begun to be unraveled, with the discovery of mutations in potassium channel (KCNJ5), ATPases (ATP1A1, ATP2B3), and calcium channel (CACNA1D), and aberrant Wnt/ß- catenin signaling. The most recent data suggest that 95% of cases are sporadic, whereas 5% of cases are hereditary. Pathologic correlates of primary aldosteronism include adrenal cortical hyperplasia, adenoma, and carcinoma. Although the most common clinical presentation is bilateral adrenal cortical hyperplasia, this entity is usually treated medically. Therefore, in the setting of primary aldosteronism, surgical pathologists are most commonly exposed to adrenocortical adenomas and the odd occa- sional carcinoma. This review provides an update on the current knowledge of primary aldosteronism and discusses the clinicopathologic correlations of this important dis- ease.
(Arch Pathol Lab Med. 2015;139:948-954; doi: 10.5858/ arpa.2014-0156-RS)
F irst described by Conn in 1955, primary aldosteronism is defined as a group of disorders in which aldosterone production is inappropriately elevated, relatively indepen- dent from the renin-angiotensin system, and nonsuppres- sible by sodium loading.1-4 Our understanding of this disease has evolved drastically in the last decade with the advent of biochemical screening using plasma aldosterone to renin ratio (ARR).1-7 Previously thought to be a rare and relatively benign cause of hypertension, primary aldoste- ronism is currently recognized as the leading cause of secondary hypertension, with a prevalence of 5% to 13% among hypertensive adults.1-5 Furthermore, it incurs signif- icant cardiovascular morbidity and mortality, which are specific to aldosterone itself.1-5
Pathologic correlates of primary aldosteronism include adrenal cortical hyperplasia, adenoma, and carcinoma. The
diagnostic features of these entities have been refined during the past decade with the advent of modern imaging, biochemical testing, and molecular pathology.8-10 Primary aldosteronism is now known to comprise both sporadic (95%) and familial (5%) forms.11 Bilateral adrenal hyperpla- sia (idiopathic hyperaldosteronism) accounts for 65% of sporadic cases of primary aldosteronism.1-4 With the advent of adrenal vein sampling, these lesions are almost never encountered in surgical pathology, because virtually all of the cases are treated medically.12,13 Rare cases of unilateral adrenal hyperplasia causing primary aldosteronism (2%) have been reported to benefit from surgical treatment1-4,7; however, the spectrum of morphologic changes in this context has not been extensively described. Aldosterone- producing adrenal cortical adenoma accounts for the remaining 30% of sporadic cases1-7 and is the most commonly encountered aldosterone-producing lesion in surgical pathology practice. Adrenocortical carcinoma has also been reported in 1% of cases of sporadic primary aldosteronism.1-7
CLINICAL AND LABORATORY FEATURES
In clinical practice, primary aldosteronism is equally reported in both sexes, with a peak incidence between ages 30 and 60 years; it is rarely seen in children.1-4 Normoka- lemic hypertension is the most common presentation, with hypokalemia present only in severe cases.1-5 Unlike patients with Cushing syndrome or adrenogenital syndrome, most patients with primary aldosteronism are usually asymptom- atic and do not harbor any specific physical findings.1-5 Occasionally, some patients with marked hypokalemia may have symptoms such as muscle weakness and cramping, headaches, palpitations, polydipsia, polyuria, nocturia, or a combination of these.1-4
Primary aldosteronism is a laboratory diagnosis. The vast majority of cases are detected during routine biochemical screening of population groups with higher reported rates of primary aldosteronism.1-5 These include patients with refrac- tory hypertension, hypokalemia, suggestive family history, or an incidentally detected adrenal mass.1-5 The current gold standard screening test is the plasma ARR.1-5 The most commonly adopted cutoff value of ARR is 30 ng/dL per ng/ mL per hour (or 750 pmol/L per ng/ml per hour).1 When the ARR value is higher than the cutoff, the diagnosis of primary aldosteronism is confirmed or excluded by an aldosterone suppression test. The most widely used confirmatory tests are intravenous saline loading, oral sodium loading, fludrocorti- sone suppression, and captopril challenge test.1-5 Occasion- ally, primary aldosteronism is diagnosed as part of the workup for an incidentaloma, in which case special attention should be given to the biochemical results of an overnight
From the Department of Pathology, University Health Network, and the Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Ozgur Mete, MD, Department of Pathology, University Health Network, 200 Elizabeth St, 11th Floor, Toronto, ON M5G 2C4, Canada (e-mail: ozgur.mete2@uhn.ca).
| Overview of Familial Hyperaldosteronism (FH)a | ||||
|---|---|---|---|---|
| FH Type | Inheritance | Associated Gene | Clinical Features | Pathologic Features |
| FH-I | Autosomal dominant | CYP11B1, CYP11B2 | Early onset (often before age 20 y), resistant hypertension, mostly normokalemic, complete aldosterone response to dexamethasone | Normal adrenal glands; occasional adrenal cortical nodular disease or bilateral hyperplasia |
| FH-II | Autosomal dominant; undetermined in some cases | Unknown; linked to 7p22 | Clinical features indistinguishable from sporadic primary aldosteronism: onset in adulthood, resistant hypertension, mostly normokalemic | Adrenal cortical adenoma or bilateral hyperplasia |
| FH-III | Autosomal dominant | KCNJ5 | Very early onset (childhood), severely resistant hypertension, hypokalemia, very high aldosterone concentrations (2-10 times normal concentrations) | Marked bilateral adrenal hyperplasia; occasional normal adrenal glands |
a Data derived from Bar-lev and Annes,6 Zennaro et al,8 Scholl and Lifton,10 and Mulatero et al.11
dexamethasone suppression test and 24-hour urinary mea- surement of fractionated metanephrines and catecholamines, to exclude Cushing or subclinical Cushing syndrome and pheochromocytoma.14
In sporadic primary aldosteronism, some clinical and laboratory features are distinctive of hyperplasia (idiopathic hyperaldosteronism), adenoma, or carcinoma.1-4,7 Primary aldosteronism caused by adrenal cortical hyperplasia usually presents in older individuals, has a predominance among males, is more often normokalemic, and has less severe hypertension.1-4,7 By contrast, aldosterone-producing ade- nomas usually appear at an earlier age, occur more often in females, and are more often associated with hypokalemia and severe hypertension.1-4,7 When primary aldosteronism is caused by an adrenocortical carcinoma, it usually presents with much more profound hypokalemia, very high aldoste- rone concentrations, and in some cases concurrent cortisol and/or sex-steroid production, leading to Cushing syn- drome or virilization.7,15,16
Three types of familial primary aldosteronism have also been identified-all are inherited in an autosomal- dominant manner (Table).5-11 Familial hyperaldosteronism type I, also known as glucocorticoid-remediable aldoste- ronism, has been attributed to less than 1% of cases of primary aldosteronism and is caused by a recombination between the CYP11B2 and CYP11B1 genes.11 Familial hyperaldosteronism type II is responsible for 3% to 5% of cases of primary aldosteronism and has been linked to 7p22, although no specific gene has been identified to date.5-11 Familial hyperaldosteronism type III is a more recent discovery and has been found in less than 1% of cases, involving mutations in a potassium channel (KCNJ5).11
Hereditary forms of primary aldosteronism typically manifest more florid symptoms, with the exception of familial hyperaldosteronism type II, which is clinically and biochemically indistinguishable from sporadic cases.6,11 Familial hyperaldosteronism type II is usually only diag- nosed when at least two first-degree members of the same family have confirmed primary aldosteronism and after familial hyperaldosteronism types I and III have been excluded.6,11 Most individuals with familial hyperaldoste- ronism type I develop severe hypertension early in life (before the age of 20 years) and display high rates of morbidity and mortality from cerebrovascular events, although milder clinical phenotypes have also been report- ed.11 A defining feature of familial hyperaldosteronism type I is that administration of exogenous glucocorticoids reverses the state of mineralocorticoid excess.1-5 Individuals with
familial hyperaldosteronism type III typically develop an early-onset and particularly severe form of primary aldo- steronism, with very high aldosterone concentrations (2-10 times normal concentrations), marked hypokalemia, and severe hypertension resistant to medical therapy.11
RADIOLOGIC FEATURES
Once primary aldosteronism is confirmed biochemically, radiologic investigations provide a preliminary method for localization and subtyping of aldosterone-producing lesions. Adrenal computed tomography (CT) scan is the initial modality of choice.1-4,17,18 The findings on CT for adrenal hyperplasia are usually nonspecific, showing either enlarged or normal-size adrenal glands.7 Adrenal adenomas usually appear homogeneous, round, and small, with smooth borders and well-delineated margins (Figure 1, A).14,17,18 Radiologic features of tumors suspicious for adrenocortical carcinoma include larger size (>4 cm), irregular margins, inhomogeneous contents, and areas of necrosis, hemor- rhage, and calcification.1-4,14,17,18 Because of the fact that adenomas often have intracytoplasmic fat, resulting in lower attenuation, measurement of the attenuation value in Hounsfield units is helpful in distinguishing adenomas from nonadenomas14,18; tumors with attenuation values of less than 10 Hounsfield units on an unenhanced CT are often diagnostic of adrenocortical adenomas (Figure 1, A).14,18 It is important to note, however, that CT cannot reliably visualize microadenomas or hyperplasia, or determine the functional status of an adrenal cortical adenoma.1-4,14,17,18
Given the limitations of adrenal CT scan, adrenal venous sampling has become the gold standard test to determine lateralization of the source of the excessive aldosterone secretion.1-4,17 This method is also helpful in differentiating aldosterone-producing adenoma from bilateral adrenal hyperplasia.17 After successful catheterization of both adrenal veins under interventional radiology, comparison of the aldosterone to cortisol ratio between both sides is the currently accepted criterion for determining unilateral versus bilateral disease.17 This is also known as the lateralization index (aldosterone-to-cortisol ratio on the dominant side divided by the aldosterone-to-cortisol ratio on the non- dominant side). Most investigators concur that a lateraliza- tion index of 4 or higher during cosyntropin stimulation (≥2 for unstimulated adrenal vein sampling) is indicative of unilateral aldosterone production and favors the diagnosis of aldosterone-producing adenoma, whereas a lateralization index lower than 4 is more suggestive of bilateral
A
B
C
D 1
E
F
aldosterone production involving bilateral adrenal hyper- plasia.17
GROSS FEATURES
The normal adult adrenal gland weighs 4 g at surgical excision,12,15,16 with an average cortical thickness of almost 2 mm.12 However, there may be variation from gland to gland or thicker areas in different parts of the same gland.12 Grossly, adrenal gland with hyperplasia (idiopathic hyper- aldosteronism) may appear unremarkable or show slight enlargement, with grossly visible micronodules or macro- nodules.12,13 Aldosterone-producing adenomas often pre- sent with a round-to-ovoid unicentric neoplasm measuring a few centimeters in diameter.12,13,15,16,19 Most adenomas are unilateral and solitary, but occasional bilateral adenomas have also been reported.13,16,19 These tumors are often intra- adrenal and unencapsulated, but some may also show a true capsule or a pseudocapsule.12,15,16 The cut surface is classically described as homogenous, and golden yellow or “canary yellow” (Figure 1, B), and larger tumors may have areas of hemorrhage or cystic change.12,13,15,16,19 Adrenocor- tical carcinomas usually weigh more than 100 g, and can measure from 3 to 40 cm15,16, some are encapsulated, but many are adherent to or invade adjacent structures.15,16 On slicing, they often show lobulation with fibrous bands and areas of necrosis and hemorrhage.15,16
The gross features of familial hyperaldosteronism are scarcely reported in the literature. In type I, macroscopic examination usually reveals normal adrenal glands, al- though some cases showing adrenal cortical nodular disease and massive bilateral adrenal hyperplasia have been described.11,20 In type II, gross examination can reveal either adrenal cortical adenoma or bilateral hyperplasia.11 In type III, the adrenal glands show marked bilateral hyperplasia, which can be seen grossly, although normal adrenal glands have also been described in some families.11
During the gross examination, particular attention should be given to the width of the cortex.13,15,19,24 Even grossly, the identification of atrophy of the nontumorous adrenal cortex in a gland with a dominant cortical adenoma should prompt the attention of the surgical pathologist to determine whether the patient has been diagnosed with concurrent Cushing syndrome. If not, a timely call to the treating physician will prevent the unanticipated postoperative crisis of acute Addison disease.21
HISTOPATHOLOGIC FEATURES
The histopathologic correlates of primary aldosteronism include adrenal cortical hyperplasia, adenoma, and carcino- ma. Although adrenal cortical hyperplasia is the most common clinical presentation, this entity rarely presents itself in surgical pathology, because most cases involve bilateral glands and are treated medically.12,13 Although rare examples of unilateral adrenal cortical hyperplasia have been reported in patients with primary aldosteronism, the spectrum of morphologic changes has not been extensively defined in this setting.1-7,12,13 Therefore, with the exception of paradoxic zona glomerulosa (ZG) hyperplasia, patholo- gists are most commonly exposed to adrenal cortical neoplasms, especially adenomas, from patients with primary aldosteronism.12,13,15,16,19
On light microscopy, aldosterone-producing adrenal cortical adenomas appear partially or completely encapsu- lated, with a compressed fibrous rim or fibrous “pseudo-
capsule” at the expansile borders of the tumor (Figure 1, C).12,15,16 Tumor cells often present in a nesting or alveolar pattern, as short cords, as blunt anastomosing trabeculae, or as mixtures of these architectural patterns.12 The morphol- ogy of individual cells may be quite heterogeneous, with varying proportions of 4 different types of cells: clear cells resembling zona fasciculata cells, cells resembling ZG cells, compact cells indistinguishable from those of the zona reticularis, and a group of cells designated as “hybrid” cells with cytologic features of both zona fasciculata and ZG cells.12,13,15,19-22 Lipid-rich clear cells usually predominate in these lesions, giving them a characteristic golden yellow color.12,15,19,21,22 Similar to other endocrine lesions, oncocytic change has also been reported in the literature.12,22 Some cases exhibit cytoplasmic eosinophilic globular inclusions, reflecting degenerated mitochondria.22
Occasionally, the existence of a cortisol-producing ade- noma may be missed by the clinician preoperatively. Although this may be due to an omission, a variant of aldosterone-producing adenoma with concurrent cortisol production has also been described.23 The distinction between cortisol-producing adenoma and aldosterone- producing adenoma can be made on hematoxylin-eosin- stained slides by assessing the nontumorous adrenal cortex.12,21,22 Cortisol-producing adrenal cortical adenomas are associated with atrophy of the nontumorous cortex due to the negative feedback suppression effect of the hypotha- lamic-pituitary axis.12,13,21,22
Unlike glucocorticoid-producing adenomas, aldosterone- producing cortical neoplasms are not associated with cortical atrophy,12,13,15,19-22 and paradoxical ZG hyperplasia can be identified in the nontumorous adrenal cortex (Figure 1, D).12,13,15,19-22 The ZG is composed of small angular cells with a high nuclear to cytoplasm ratio, dispersed focally below the capsule. In other words, the presence of a continuous ZG layer is a sign of hyperplasia. The presence of spironolactone bodies within an adrenal cortical adenoma provides another morphologic clue leading to recognition of aldosterone production.12,15,19-22 These are described as intracytoplasmic eosinophilic inclusions following spirono- lactone treatment (Figure 1, E).12,15,19-22 These inclusions are often small (2-12 um), round to oval, and delineated from surrounding cytoplasm by a small, clear halo.12 Red blood cells and other intracytoplasmic inclusions can sometimes mimic spironolactone bodies. Although a distinctive feature of spironolactone bodies is their concentric and lamellated pattern, Luxol fast blue stain can also be used to distinguish these inclusions from other mimickers because of their rich content of phospholipids (Figure 1, F).12
Despite being a rare cause of primary aldosteronism, adrenocortical carcinoma must be excluded, particularly if a large tumor is found.1-4,12,13,15,19 Histologic examination reveals a more disorganized architecture than in adenomas, with trabecular and diffuse patterns.12,13,15,19,24 Nuclear pleomorphism and increased mitoses (>5 per 50 high- power fields), including atypical figures, are often present, along with capsular and/or vascular invasion in the vast majority of high-grade adrenocortical carcinomas.12,13,15,19,24 However, making the distinction between a noninvasive low-grade adrenocortical carcinoma and adrenal cortical adenoma with atypical features can be challenging. Al- though many scoring schemes have been defined in this field, even the most commonly used Weiss scoring scheme carries significant interobserver variability, along with a gray zone when an adrenal cortical neoplasm receives a score of
Voltage gated Ca2+ channel
Na*
Ca2+
30000
JUO
32000
2
0000000000
XOXOXO
00000
doxodooooo
K*
K·
Na+
K· channel
AT2R
Na*/K* ATPase
Na*/Ca2+ ATPase
Hyperpolarization
Ca2.
Ca2+
8
ATPase
A
CYP11B2
1
Voltage gated Ca2+ channel
AT2
Na*
Ca2+
300000
00000
00000
00000
0000000Co
500000
dodoo
00000
00000
000000000X
2
K*
K· channel
Na+/K* ATPase
Na*
AT2R
Na*/Ca2+ ATPase
4
Ca3.
3
Ca2+
Depolarization
Ca2.
Ca2+
Ca2+ ATPase
5
Aldosterone
B
CYP1182
6
Na*
Ca ?·
3- Mutant voltage gated Ca ?. channel (CACNA1D)
-Na*
000000
00000
00000
8000
000000999
BOOOOO
00000
cocco
OOOOO
doodooxx
Na*
K*
1- Mutant K+ channel (KCNJS)
AT2R
Na*
2- Mutant Na*/K· ATPase (ATP1A1)
Na+/Ca2+ ATPase
Ca2+
Ca2+
Ca2+
Ca2
Depolarization
4- Mutant Ca2.
ATPase (ATP283)
Aldosterone
C
CYP11B2
8
2 or 3. Recently, Volante et al25 introduced a simplified approach by using the “reticulin algorithm” to define malignancy through an altered reticulin network associated with one of the following parameters: high mitotic rate (>5 mitoses per 50 high-power fields), vascular invasion, and necrosis. This method has subsequently been shown to have a high interobserver reproducibility.26 Furthermore, insulin-
like growth factor 2 and p53 overexpression, and a high amount of Ki-67 (>5%) have also been shown to be effective in differentiating carcinoma from adenoma.15,16,24
ANCILLARY STUDIES
The ultrastructural features of aldosterone-producing adenomas are unique. Aldosterone-producing cells contain mitochondria with lamella-type or platelike cristae, charac- teristic of ZG-type cells, whereas glucocorticoid-producing and nonfunctioning adenoma cells contain mitochondria with tubulovesicular cristae.12,13,21,22 Furthermore, ultrastruc- tural spironolactone bodies, consisting of a central core with amorphous, electron-dense material surrounded by multiple concentric membranes, are seen in aldosterone-producing adenoma. 12,13,21,22
Currently, immunohistochemical tests are not part of the routine histopathologic assessment of aldosterone-produc- ing lesions, because most cases can be given a diagnosis using conventional histology in conjunction with biochem- ical evidence of primary aldosteronism.12,13,15,19-22 In the past, some investigators have used positive P450(c17) and 3ß-hydroxysteroid dehydrogenase immunostaining as evi- dence of steroid production in aldosterone-producing cells, although these also stain positive in cortisol-producing cells.13,27,28 Recently, two studies concurrently described the use of a novel immunostain, CYP11B2, to confirm the production of aldosterone and the histopathologic diagnosis of primary aldosteronism.27,28 CYP11B2 is a key enzyme for aldosterone synthesis, and positive staining for CYP11B2 is indicative of cells producing aldosterone in both tumor and in the ZG of adjacent tissue.27,28 Occasionally, when there is a need to distinguish an adrenal cortical adenoma from another tumor, one can confirm the adrenal cortical origin by demonstrating positivity for universal markers of adrenal cortical cytodifferentiation, including steroidogenic factor-1, Melan-A (clone A103), calretinin, synaptophysin, and a- inhibin.
PATHOGENESIS AND MOLECULAR BIOLOGIC FEATURES
In normal physiology, aldosterone is secreted by the adrenal cortex in response to hyperkalemia and angiotensin II.6,8-10 The responsive cells are typically hyperpolarized because of predominant K+ conductance, which is primarily mediated by K+ channels.6,8-10 Activation of the renin- angiotensin system leads to the production of angiotensin II, which binds to type 1 angiotensin II receptor, inhibiting potassium currents and inducing cell membrane depolar- ization (Figure 2, A and B).6,8-10 Depolarization subsequently activates low-voltage-activated calcium channels, leading to calcium influx.6,8-10 The resulting activation of the calcium/ calmodulin kinase pathway leads to increased production of rate-limiting enzymes for aldosterone synthesis. In addition to this acute effect, chronic Ca2+ signaling also stimulates ZG proliferation.6,8-10
The molecular mechanism underlying autonomous aldo- sterone production from the adrenal cortex has only begun to be unraveled recently.8-10 Primary aldosteronism occurs in a number of familial syndromes. The causal genes underlying two hereditary forms of primary aldosteronism have been identified.5,6,8,10,11 These include rearrangement of CYP11B1/CYP11B2 genes in type I familial hyperaldoste- ronism, and germ line mutations in KCNJ5 (T158A and G151R) in type III familial hyperaldosteronism (Figure 2, C).
Although the causal gene underlying type II familial hyperaldosteronism has not yet been identified, some reports have linked it to chromosome 7p22.5,6,8,10,11
During the past 2 years, considerable interest has been generated by the discovery of sporadic mutations in potassium channels (KCNJ5), calcium channels (CACNA1D), and ATPases (ATP1A1 and ATP2B3; Figure 2, C). Together, these 4 mutations account for approximately 60% of aldosterone-producing adenomas.29-33 KCNJ5 encodes Kir3.4, an inward rectifier potassium channel in ZG layer cells.8-11 Two common somatic gain-of-function mutations (G151R and L168R) located in or close to the KCNJ5 selectivity filter have been reported in 40% of aldosterone- producing adenomas.8-11 The mechanism underlying aldo- sterone production and cell proliferation is the sodium permeability of the mutant KCNJ5 channel, causing cellular depolarization and calcium influx through voltage-gated calcium channels.8-11 Recently, a lower expression of the KCNK5 gene encoding Twik-related Acid-sensitive K+ channels 2 (TASK2) has also been described in aldoste- rone-producing adenomas and was shown to increase production of aldosterone in vitro.33 Some investigators suggested that KCNJ5 mutations are more prevalent in aldosterone-producing adenomas resembling clear cells of the zona fasciculata but are absent in a subset of aldosterone-producing adenomas resembling small angular cells of the ZG cells.30 Exon sequencing of the latter group identified somatic mutations in either ATP1A1 or CAC- NA1D, which could suggest a common subtype of aldosterone-producing adenoma.30 Many adenomas har- boring these mutations were less than 1 cm in diameter and had been overlooked on conventional adrenal imaging.30
ATP1A1 (encoding Na+/K+ ATPase a subunit) and ATP2B3 (encoding Ca2+ATPase) play an important role in the regulation of aldosterone production by maintaining cell membrane potential.30,31 Mutations in the Na+/K+ ATPase a subunit lead to a loss of pump activity and reduced affinity for K+ (Figure 2, C).30,31 Deletions in ATP2B3 are inferred to cause distortion of the Ca2+-binding site and to affect intracellular calcium clearance (Figure 2, C).30,31 Another study identified somatic mutations (Gly403 and Ile770) in the CACNA1D gene, which encodes a voltage-gated calcium channel (Cav1.3; Figure 2, C).30,32 The altered residues cause channel activation at less depolarized potentials. G1403 alterations also impair channel inactivation.30,32 These effects are inferred to cause increased Ca2+ influx, which in turn stimulates aldosterone production and cell proliferation.30,32
In the adrenal gland, dysregulation of the Wnt/B-catenin signaling pathways has already been reported in the development of micronodular and macronodular hyperpla- sia and adrenocortical neoplasms.24,30,34 Recently, a study has shown that Wnt/ß-catenin signaling is aberrantly activated in 70% of aldosterone-producing adenomas in a series of 47 patients.34 This study also provides further evidence that decreased expression of the Wnt inhibitor SFRP2 may be contributing to dysregulated Wnt signaling and aldosterone-producing adenoma development in some patients.34
TREATMENT AND PROGNOSIS
Unilateral laparoscopic adrenalectomy is currently the gold standard for treatment of aldosterone-producing adenomas and often results in improved blood pressure and serum concentrations postoperatively.1-5 In bilateral
adrenal hyperplasia (idiopathic hyperaldosteronism), the preferred treatment is usually pharmacologic, using miner- alocorticoid antagonists.1-4 Although spironolactone is still recommended as the primary agent, eplerenone has been described as an alternative option.1 In rare cases of unilateral adrenal hyperplasia, unilateral adrenalectomy has been shown to be beneficial, although the long-term outcome of surgery has not been extensively reported.1-5 Aldoste- rone-producing adrenocortical carcinoma is treated similarly to other adrenocortical carcinomas, with surgical resection and adjuvant mitotane treatment.4,35 The guidelines for the testing of familial hyperaldosteronism have not been firmly established.1-7,11 Currently, only screening for familial hyperaldosteronism type I has been recommended in patients with early onset of primary aldosteronism and those with a family history of primary aldosteronism or stroke at a young age.1 The initial treatment for familial hyperaldosteronism type I consists of low-dose dexameth- asone; spironolactone or amiloride may also be considered if treatment with glucocorticoid does not normalize blood pressure.1-4
CONCLUSION
Despite emerging evidence using genomic sequencing, there is still much debate regarding the molecular mecha- nisms leading to hyperaldosteronism, cell proliferation, and tumor formation. Pathologic correlates of primary aldoste- ronism include adrenal cortical hyperplasia, adenoma, and carcinoma. Although each aldosterone-producing lesion possesses particular clinical, laboratory, and radiologic findings, preoperative subtyping may be difficult in some cases. Therefore, it is important for the practicing pathol- ogist to recognize the spectrum of primary aldosteronism and differentiate aldosterone-producing adrenal cortical adenoma from hyperplasia and carcinoma, because it is of tremendous importance for management.
References
1. Funder J, Carey R, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
2. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-618.
3. Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006;2(4):198-208.
4. Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn’s syndrome. Nat Clin Pract Endocrinol Metab. 2007; 3(3):220-227.
5. Funder JW. The genetic basis of primary aldosteronism. Curr Hypertens Rep. 2012;14(2):120-124.
6. Bar-lev A, Annes JP. Genetics of adrenocortical disease: an update. Curr Opin Endocrinol Diabetes Obes. 2012;19(3):159-167.
7. Ganguly A. Primary aldosteronism. N Engl J Med. 1998;339(25):1828- 1834.
8. Zennaro MC, Rickard AJ, Boulkroun S. Genetics of mineralocorticoid excess: an update for clinicians. Eur J Endocrinol. 2013;169(1):R15-R25.
9. Gomez-Sanchez CE, Oki K. Minireview: potassium channels and aldosterone dysregulation: is primary aldosteronism a potassium channelopathy? Endocrinology. 2014;155(1):47-55.
10. Scholl UI, Lifton RP. New insights into aldosterone-producing adenomas and hereditary aldosteronism: mutations in the K+ channel KCNJ5. Curr Opin Nephrol Hypertens. 2013;22(2):141-147.
11. Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9(2):104-112.
12. Lack EE. Tumors of the Adrenal Glands and Extraadrenal Paraganglia. Washington, DC: ARP Press; 2007. Atlas of Tumor Pathology; 4th series, fascicle 8.
13. Sasano H. The adrenal cortex. In Stefaneanu L, Sasano H, Kovacs K, eds. Molecular and Cellular Endocrine Pathology. London, England: Arnold; 2000: 221-252.
14. Young WF. Clinical practice: the incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610.
15. McNicol AM. Update on tumours of the adrenal cortex, phaeochromo- cytoma and extra-adrenal paraganglioma. Histopathology. 2011;58(2):155-168. 16. McNicol AM. Lesions of the adrenal cortex. Arch Pathol Lab Med. 2008; 132(8):1263-1271.
17. Sacks BA, Brook OR, Brennan IM. Adrenal venous sampling: promises and pitfalls. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):180-185.
18. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14(3):587-599.
19. DeLellis RA, ed. Pathology & Genetics: Tumours of Endocrine Organs. Vol 8. Lyon, France: IARC Press; 2004.
20. Velarde-Miranda C, Gomez-Sanchez EP, Gomez-Sanchez CE. Regulation of aldosterone biosynthesis by the Kir3.4 (KCNJ5) potassium channel. Clin Exp Pharmacol Physiol. 2013;40:895-901.
21. Mete O, Asa SL. Morphological distinction of cortisol-producing and aldosterone-producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. Histopathology. 2012;60(6):1015-1016.
22. Mete O, Asa SL. Aldosterone-producing adrenal cortical adenoma with oncocytic change and cytoplasmic eosinophilic globular inclusions. Endocr Pathol. 2009;20(3):182-185.
23. Späth M, Korovkin S, Antke C, Anlauf M, Willenberg HS. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol. 2011;164(4):447-455.
24. McNicol AM. Diagnostic and molecular aspects of adrenal cortical tumors. Semin Diagn Pathol. 2013;30(3):197-206.
25. Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55(5):535-543.
26. Duregon E, Fassina A, Volante M, et al. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013;37(9):1433-1440.
27. Nanba K, Tsuiki M, Sawai K, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. J Clin Endocrinol Metab. 2013;98(4):1567-1574.
28. Volpe C, Höög A, Ogishima T, et al. Immunohistochemistry improves histopathologic diagnosis in primary aldosteronism. J Clin Pathol. 2013;66(4): 351-354.
29. Young DMJ, Fuller PJ, Stowasser M, Mihailidou AS. Introduction. Clin Exp Pharmacol Physiol. 2013;40:872-875.
30. Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45(9):1055-1060.
31. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hyperten- sion. Nat Genet. 2013;45(4):440-444.
32. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050-1054.
33. Lenzini L, Caroccia B, Campos AG, et al. Lower expression of the TWIK- related acid-sensitive K+ channel 2 (TASK-2) gene is a hallmark of aldosterone- producing adenoma causing human primary aldosteronism. J Clin Endocrinol Metab. 2014;99(4):e674-e682.
34. Berthon A, Drelon C, Ragazzon B, et al. WNT/ß-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone produc- tion. Hum Mol Genet. 2014;23(4):889-905.
35. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-4564.